BIOFRONTERA INC. WARRANTS
NASDAQ: BFRIW (Biofrontera Inc. Warrants)
Kemas kini terakhir: 9 jam lalu0.040
-0.02 (-27.49%)
| Penutupan Terdahulu | 0.055 |
| Buka | 0.097 |
| Jumlah Dagangan | 16,736 |
| Julat 52 Minggu |
| Margin Keuntungan | -30.33% |
| Margin Operasi (TTM) | -52.95% |
| EPS Cair (TTM) | -1.30 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 8.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,036.89% |
| Nisbah Semasa (MRQ) | 1.40 |
| Aliran Tunai Operasi (OCF TTM) | -11.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.28 M |
| Pulangan Atas Aset (ROA TTM) | -49.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -384.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Biofrontera Inc. Warrants | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | 0.13 |
|
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bard Associates Inc | 31 Dec 2025 | 154,900 |
| Us Bancorp \De\ | 31 Dec 2025 | 1,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |